142 related articles for article (PubMed ID: 34439127)
1. The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.
Masisi BK; El Ansari R; Alfarsi L; Craze ML; Jewa N; Oldfield A; Cheung H; Toss M; Rakha EA; Green AR
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439127
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
[TBL] [Abstract][Full Text] [Related]
3. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
Craze ML; Cheung H; Jewa N; Coimbra NDM; Soria D; El-Ansari R; Aleskandarany MA; Wai Cheng K; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Br J Cancer; 2018 Jan; 118(2):258-265. PubMed ID: 29169183
[TBL] [Abstract][Full Text] [Related]
4. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
5. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
6. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer.
Saha SK; Islam SMR; Abdullah-Al-Wadud M; Islam S; Ali F; Park KS
J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30871151
[TBL] [Abstract][Full Text] [Related]
7. Structure and activation mechanism of the human liver-type glutaminase GLS2.
Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase (GLS1) gene expression in primary breast cancer.
Vidula N; Yau C; Rugo HS
Breast Cancer; 2023 Nov; 30(6):1079-1084. PubMed ID: 37679553
[TBL] [Abstract][Full Text] [Related]
10. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Aguiar FN; Mendes HN; Bacchi CE; Carvalho FM
Rev Bras Ginecol Obstet; 2013 Mar; 35(3):97-102. PubMed ID: 23538467
[TBL] [Abstract][Full Text] [Related]
12. The role of glutaminase in cancer.
Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
[TBL] [Abstract][Full Text] [Related]
13. Squalene epoxidase expression is associated with breast tumor progression and with a poor prognosis in breast cancer.
Kim NI; Park MH; Kweon SS; Cho N; Lee JS
Oncol Lett; 2021 Apr; 21(4):259. PubMed ID: 33664822
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes.
Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Segura JA; Alonso FJ; Márquez J
Curr Med Chem; 2020; 27(32):5317-5339. PubMed ID: 31038055
[TBL] [Abstract][Full Text] [Related]
15. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
[TBL] [Abstract][Full Text] [Related]
18. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
19. Expression of Gls and Gls2 glutaminase isoforms in astrocytes.
Cardona C; Sánchez-Mejías E; Dávila JC; Martín-Rufián M; Campos-Sandoval JA; Vitorica J; Alonso FJ; Matés JM; Segura JA; Norenberg MD; Rama Rao KV; Jayakumar AR; Gutiérrez A; Márquez J
Glia; 2015 Mar; 63(3):365-82. PubMed ID: 25297978
[TBL] [Abstract][Full Text] [Related]
20. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Khout H; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2018 Dec; 119(12):1518-1526. PubMed ID: 30410060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
